2024
A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device for the Treatment of Pulmonary Embolism (ENGULF)
Kobayashi T, Secemsky E, Klein A, Faintuch S, Bulman J, Weinstein J, Bitton-Faiwiszewski Y, Bisharat M, Metzger D, Rosenberg R, Weinberg I, Vadlamudi V, Matthai W, Saleh A, Cristea E, Lansky A, Giri J. A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device for the Treatment of Pulmonary Embolism (ENGULF). Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102049. PMID: 39132596, PMCID: PMC11307881, DOI: 10.1016/j.jscai.2024.102049.Peer-Reviewed Original ResearchIntermediate-risk PELife-threatening bleedingPulmonary embolismRV/LV ratioAcute PEAdverse eventsThrombectomy catheterPostprocedure computed tomography angiographyTreatment of acute PEDevice-related serious adverse eventsTreatment of pulmonary embolismFirst-in-human studyPreprocedural computed tomography angiographyCatheter-directed embolectomyRight ventricle/left ventricleSecondary safety outcomesVARC-2 criteriaSerious adverse eventsDays post-procedureSingle-arm studyRisk of mortalityPrimary efficacyVARC-2Embolectomy devicesHours postprocedure
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose